[go: up one dir, main page]

ECSP12011835A - Moléculas de unión biespecíficas para la terapia anti-angiogénesis. - Google Patents

Moléculas de unión biespecíficas para la terapia anti-angiogénesis.

Info

Publication number
ECSP12011835A
ECSP12011835A ECSP12011835A ECSP12011835A EC SP12011835 A ECSP12011835 A EC SP12011835A EC SP12011835 A ECSP12011835 A EC SP12011835A EC SP12011835 A ECSP12011835 A EC SP12011835A
Authority
EC
Ecuador
Prior art keywords
bispecific
angiogenesis therapy
molecules
dii4
vegf
Prior art date
Application number
Other languages
English (en)
Inventor
Eric Borges
Andreas Gschwind
Joachim Boucneau
Travernier Evelyn De
Joost Kolkman
Pascal Merchiers
Hoorick Diane Van
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43431796&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP12011835(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of ECSP12011835A publication Critical patent/ECSP12011835A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)

Abstract

Moléculas de unión biespecíficas, en particular dominios variables sencillos de inmunoglobulina tales como VHH y anticuerpos de dominio, que comprenden un componente de unión a VEGF y un componente de unión a DII4 en una molécula. Composiciones farmacéuticas que contienen los mismos y su uso en el tratamiento de enfermedades que están asociadas con efectos mediados por VEGF y DII4 sobre la angiogénesis. Ácidos nucleicos que codifican las moléculas de unión biespecíficas, células hospedadoras y métodos para prepararlas.
ECSP12011835 2009-10-02 2012-04-26 Moléculas de unión biespecíficas para la terapia anti-angiogénesis. ECSP12011835A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09172137 2009-10-02
EP10175316 2010-09-03

Publications (1)

Publication Number Publication Date
ECSP12011835A true ECSP12011835A (es) 2012-06-29

Family

ID=43431796

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP12011835 ECSP12011835A (es) 2009-10-02 2012-04-26 Moléculas de unión biespecíficas para la terapia anti-angiogénesis.

Country Status (24)

Country Link
US (2) US20110172398A1 (es)
EP (1) EP2483314A1 (es)
JP (2) JP5833009B2 (es)
KR (1) KR20120101375A (es)
CN (2) CN105037542A (es)
AP (1) AP2012006188A0 (es)
AR (1) AR078515A1 (es)
AU (1) AU2010302589A1 (es)
BR (1) BR112012007239A2 (es)
CA (1) CA2775422A1 (es)
CL (1) CL2012000826A1 (es)
EA (1) EA201200548A1 (es)
EC (1) ECSP12011835A (es)
IL (1) IL218542A0 (es)
IN (1) IN2012DN02752A (es)
MA (1) MA33607B1 (es)
MX (1) MX2012003897A (es)
NZ (2) NZ626302A (es)
PE (1) PE20121024A1 (es)
PH (1) PH12012500525A1 (es)
TN (1) TN2012000145A1 (es)
TW (1) TW201124533A (es)
UY (1) UY32920A (es)
WO (1) WO2011039370A1 (es)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7750124B2 (en) * 2006-09-29 2010-07-06 Oncomed Pharmaceuticals, Inc. Anti-human DLL4 antibodies and compositions
BRPI0910482A2 (pt) 2008-04-29 2019-09-24 Abbott Lab imunoglobinas de domínio variável duplo e usos das mesmas
NZ589436A (en) 2008-06-03 2012-12-21 Abbott Lab Dual variable domain immunoglobulins and uses thereof
TW201008580A (en) 2008-06-03 2010-03-01 Abbott Lab Dual variable domain immunoglobulin and uses thereof
US8268314B2 (en) 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
EP3243835B1 (en) 2009-02-11 2024-04-10 Albumedix Ltd Albumin variants and conjugates
WO2010129304A2 (en) 2009-04-27 2010-11-11 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
WO2011025964A2 (en) 2009-08-29 2011-03-03 Abbott Laboratories Therapeutic dll4 binding proteins
UY32920A (es) * 2009-10-02 2011-04-29 Boehringer Ingelheim Int Moleculas de unión biespecíficas para la terapia anti-angiogénesis
US8883145B2 (en) 2009-10-16 2014-11-11 Oncomed Pharmaceuticals, Inc. Methods of treatment with DLL4 antagonists and an anti-hypertensive agent
ES2700230T3 (es) 2009-10-30 2019-02-14 Albumedix Ltd Variantes de albúmina
UA112743C2 (uk) 2010-03-02 2016-10-25 Еббві Інк. Терапевтичний dll4-зв'язувальний білок
PE20130207A1 (es) 2010-05-06 2013-02-28 Novartis Ag Anticuerpos antagonistas de lrp6 (proteina relacionada con lipoproteinas de baja densidad 6) y composiciones
EA201291181A1 (ru) 2010-05-06 2013-05-30 Новартис Аг Композиции и способы применения терапевтических поливалентных антител против белка, родственного рецептору липопротеинов низкой плотности 6 (lrp6)
WO2012010550A1 (en) 2010-07-19 2012-01-26 F. Hoffmann-La Roche Ag Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy
KR20130126576A (ko) 2010-07-19 2013-11-20 에프. 호프만-라 로슈 아게 항암요법에 반응할 가능성이 증가된 환자를 확인하는 방법
NZ607480A (en) 2010-08-03 2014-10-31 Abbott Lab Dual variable domain immunoglobulins and uses thereof
JP2013539364A (ja) 2010-08-26 2013-10-24 アッヴィ・インコーポレイテッド 二重可変ドメイン免疫グロブリンおよびその使用
US20120225081A1 (en) * 2010-09-03 2012-09-06 Boehringer Ingelheim International Gmbh Vegf-binding molecules
US8551479B2 (en) 2010-09-10 2013-10-08 Oncomed Pharmaceuticals, Inc. Methods for treating melanoma
WO2012068098A1 (en) * 2010-11-15 2012-05-24 Oncomed Pharmaceuticals, Inc. Methods for treating cancer with dll4 antagonists
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
US20130078247A1 (en) * 2011-04-01 2013-03-28 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to dii4 and ang2
AU2015268749B2 (en) * 2011-09-23 2017-05-25 Oncomed Pharmaceuticals, Inc. VEGF/DLL4 binding agents and uses thereof
LT3485903T (lt) * 2011-09-23 2023-02-27 Mereo Biopharma 5, Inc. Vegf/ dll4 surišantys agentai ir jų panaudojimas
AR088633A1 (es) 2011-11-04 2014-06-25 Novartis Ag Constructos extensores de vida media de lrp6 (proteina relacionada con lipoproteinas de baja densidad 6)
WO2013075066A2 (en) 2011-11-18 2013-05-23 Eleven Biotherapeutics, Inc. Proteins with improved half-life and other properties
JP2015508994A (ja) 2011-12-30 2015-03-26 アッヴィ・インコーポレイテッド Ｉｌ−１３および／またはｉｌ−１７に対する二重可変ドメイン免疫グロブリン
MX2014010278A (es) 2012-03-16 2015-03-05 Novozymes Biopharma Dk As Variantes de albumina.
CN104428315B (zh) 2012-07-13 2017-09-29 罗氏格黎卡特股份公司 双特异性抗‑vegf/抗‑ang‑2抗体及其在治疗眼血管疾病中的应用
MX2015003894A (es) * 2012-09-28 2015-07-17 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden aglutinantes duales de angiopoyetina-2 / dll4 agentes anti-vegf.
EP2900261A1 (en) * 2012-09-28 2015-08-05 Boehringer Ingelheim International GmbH Pharmaceutical combinations comprising dual angiopoietin-2 / dll4 binders and anti-vegf-r agents
US20150368329A1 (en) * 2012-10-15 2015-12-24 Oncomed Pharmaceuticals, Inc. Methods of Treating Ocular Diseases
US9599620B2 (en) 2012-10-31 2017-03-21 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with a DLL4 antagonist
MY194330A (en) 2012-11-01 2022-11-28 Abbvie Inc Anti-dll4/vegf dual variable domain immunoglobulin and uses thereof
EP3466973A1 (en) * 2012-11-01 2019-04-10 AbbVie Inc. Stable dual variable domain immunoglobulin protein formulations
EP2917233A1 (en) 2012-11-08 2015-09-16 Novozymes Biopharma DK A/S Albumin variants
BR112015023797A2 (pt) 2013-03-15 2017-10-24 Abbvie Inc proteínas de ligação de especificidade dupla dirigidas contra il-1b e/ou il-17
US10184010B2 (en) 2013-07-09 2019-01-22 Ablbio Dual-targeting protein binding specifically to DLL4 and VEGF and use thereof
US11185583B2 (en) * 2014-02-11 2021-11-30 Albany Medical College Multi-functional mucosal vaccine platform
BR112016023011A2 (pt) * 2014-04-04 2017-10-17 Oncomed Pharm Inc tratamento de câncer gástrico
US20170267784A1 (en) 2014-10-23 2017-09-21 Singh Molecular Medicine, Llc Single domain antibodies directed against intracellular antigens
EP3212233B1 (en) 2014-10-31 2020-06-24 Oncomed Pharmaceuticals, Inc. Combination therapy for treatment of disease
US10093733B2 (en) 2014-12-11 2018-10-09 Abbvie Inc. LRP-8 binding dual variable domain immunoglobulin proteins
WO2016192613A1 (zh) * 2015-06-01 2016-12-08 中山大学 具有融合至常规Fab片段的单域抗原结合片段的二价抗体
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
WO2017029407A1 (en) 2015-08-20 2017-02-23 Albumedix A/S Albumin variants and conjugates
AU2016326609B2 (en) 2015-09-23 2023-03-09 Mereo Biopharma 5, Inc. Methods and compositions for treatment of cancer
TWI746473B (zh) * 2015-11-02 2021-11-21 美商辛分子醫藥有限公司 針對細胞內抗原之單域抗體
CA3009644A1 (en) * 2015-12-04 2017-06-08 The Regents Of The University Of California Novel antibodies for the treatment of cancers
EP3453759B1 (en) * 2016-01-29 2023-08-30 Kyoto University Platelet production promoter and method of producing platelets using same
IL309890A (en) * 2017-01-30 2024-03-01 Alexion Pharma Inc Monovalent anti-properdin antibodies and antibody fragments
CN112004826B (zh) * 2018-02-05 2024-06-14 自由大学基金会 反向激动性抗us28抗体
CN111995686B (zh) * 2019-05-27 2022-06-14 兰州大学 一种具有抗血管生成活性的药物及其制备方法
TWI844709B (zh) * 2019-07-31 2024-06-11 美商美國禮來大藥廠 鬆弛素(relaxin)類似物及其使用方法
CN110452297B (zh) * 2019-09-03 2020-04-14 上海洛启生物医药技术有限公司 抗vegf单域抗体及其应用
WO2022057888A1 (zh) * 2020-09-17 2022-03-24 江苏恒瑞医药股份有限公司 特异性结合vegf和ang-2的双特异性抗原结合分子
CN112535738B (zh) * 2020-12-04 2022-09-09 中国科学技术大学 奥沙利铂偶联物及其制备方法和应用
CA3207763A1 (en) * 2021-02-10 2022-08-18 Zongda Wang Anti-vegf antibody and use thereof
CN115724968B (zh) * 2021-08-27 2023-08-08 三优生物医药(上海)有限公司 Vegf结合分子及其用途
WO2023092327A1 (en) * 2021-11-24 2023-06-01 Linno Pharmaceuticals Inc. Vegf-binding protein and use thereof
CN116063469B (zh) * 2022-08-29 2023-09-22 中山大学 一种寨卡病毒中和性纳米抗体及其制备方法与应用
CN119866346A (zh) * 2022-09-14 2025-04-22 寻济生物科技（北京）有限公司 一种抗vegfa抗体或其抗原结合片段及其应用
JPWO2024106394A1 (es) 2022-11-14 2024-05-23
CN117686722B (zh) * 2023-12-20 2024-08-09 内蒙古元牛繁育科技有限公司 一种s100a4纳米抗体及其应用
CN117860786B (zh) * 2024-03-12 2024-06-04 北京贝来药业有限公司 基因修饰间充质干细胞在多种疾病中的制药用途和诊断用途
CN120025456B (zh) * 2024-03-13 2025-11-07 寻济生物科技（北京）有限公司 一种抗vegfa融合构建体及其制备方法和应用
WO2025212751A1 (en) * 2024-04-02 2025-10-09 Therini Bio, Inc. Multi-specific antigen-binding proteins which bind human fibrin yc or fibrinogen yc domain and vascular endothelial growth factor and methods of use

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1589107B1 (en) 1992-08-21 2009-12-23 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
US6329516B1 (en) 1997-04-28 2001-12-11 Fmc Corporation Lepidopteran GABA-gated chloride channels
EP1803730A1 (en) 2000-04-12 2007-07-04 Human Genome Sciences, Inc. Albumin fusion proteins
IL156955A0 (en) 2001-01-17 2004-02-08 Genecraft Inc Binding domain-immunoglobulin fusion proteins
WO2003002609A2 (en) 2001-06-28 2003-01-09 Domantis Limited Dual-specific ligand and its use
EP1463752A4 (en) 2001-12-21 2005-07-13 Human Genome Sciences Inc ALBUMIN FUSION PROTEINS
EP2258392A1 (en) 2002-11-08 2010-12-08 Ablynx N.V. Method of administering therapeutic polypeptides
KR101103218B1 (ko) 2002-11-08 2012-01-05 아블린쓰 엔.브이. 종양 괴사 인자-알파에 대한 단일 도메인 항체 및 그 용도
US7432330B2 (en) 2002-12-31 2008-10-07 Nektar Therapeutics Al, Corporation Hydrolytically stable maleimide-terminated polymers
RU2357974C2 (ru) * 2003-01-10 2009-06-10 Аблинкс Н.В. Терапевтические полипептиды, их гомологи, их фрагменты и их применение для модуляции агрегации, опосредованной тромбоцитами
CA2529819A1 (en) 2003-06-30 2004-09-23 Domantis Limited Pegylated single domain antibodies
WO2005040219A1 (en) * 2003-10-28 2005-05-06 Novo Nordisk A/S Laminin-5 gamma2-binding peptides, related compositions, and use thereof
EP1687338B1 (en) 2003-11-07 2010-10-20 Ablynx N.V. Camelidae single domain antibodies vhh directed against epidermal growth factor receptor and uses thereof
US20050284249A1 (en) 2004-06-29 2005-12-29 Arnone David F Worm type gear mover assembly
US20080107601A1 (en) 2004-10-13 2008-05-08 Ablynx N.V. Nanobodies Tm Against Amyloid-Beta and Polypeptides Comprising the Same for the Treatment of Degenerative Neural Diseases Such as Alzheimer's Disease
US8048418B2 (en) * 2004-10-29 2011-11-01 Regeneron Pharmaceuticals, Inc. Therapeutic methods for inhibiting tumor growth with combination of Dll4 antagonists and VEGF antagonists
MX363423B (es) 2005-05-18 2019-03-22 Ablynx Nv Nanobodiestm (nanocuerpos) mejorados contra el factor alfa de necrosis del tumor.
HUE039846T2 (hu) * 2005-05-20 2019-02-28 Ablynx Nv Javított nanotestek (TM) aggregáció közvetítette rendellenességek kezelésére
US7612181B2 (en) * 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
DK1962895T3 (da) 2005-12-16 2013-03-04 Regeneron Pharma TERAPEUTISK ANVENDELSE AF EN Dll4-ANTAGONIST OG EN VEGF-HÆMMER TIL HÆMNING AF TUMORVÆKST
CN101490084A (zh) * 2006-06-06 2009-07-22 健泰科生物技术公司 抗dll4抗体及其使用方法
US20080014196A1 (en) * 2006-06-06 2008-01-17 Genentech, Inc. Compositions and methods for modulating vascular development
MX2008015541A (es) * 2006-06-06 2008-12-18 Genentech Inc Anticuerpos anti-dll4 y metodos que los usan.
JP5529536B2 (ja) * 2006-08-07 2014-06-25 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 虚血性障害又は血管不全の治療におけるＤｌｌ４アンタゴニストの使用
JP2010500876A (ja) 2006-08-18 2010-01-14 アブリンクス エン．ヴェー． Ｉｌ−６媒介性シグナル伝達に関連する疾患及び障害の治療のための、ｉｌ−６ｒに指向性を有するアミノ酸配列及びこれを含むポリペプチド
US20080132451A1 (en) * 2006-12-01 2008-06-05 Alcon Manufacturing Ltd. Modulation of polysialylated neural adhesion molecules (psa-ncam) as a regulator of ocular disease
NO347649B1 (no) 2006-12-14 2024-02-12 Regeneron Pharma Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse.
CA2678218A1 (en) * 2007-02-21 2008-08-28 Ablynx N.V. Amino acid sequences directed against vascular endothelial growth factor and polypeptides comprising the same for the treatment of conditions and diseases characterized by excessive and/or pathological angiogenesis or neovascularization
GB0709333D0 (en) * 2007-05-15 2007-06-20 Smart Targeting Ltd Binding protein
WO2009095489A2 (en) 2008-02-01 2009-08-06 Ablynx N.V. Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling
DE112009000507T5 (de) 2008-03-05 2011-02-10 Ablynx Nv Neue Antigen-bindende Dimerkomplexe, Verfahren zu ihrer Herstellung und ihre Verwendung
EP2260058A2 (en) * 2008-04-07 2010-12-15 Ablynx N.V. Single variable domains against the notch pathways
BRPI0910482A2 (pt) * 2008-04-29 2019-09-24 Abbott Lab imunoglobinas de domínio variável duplo e usos das mesmas
US8268314B2 (en) * 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
WO2010129304A2 (en) * 2009-04-27 2010-11-11 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
UY32920A (es) * 2009-10-02 2011-04-29 Boehringer Ingelheim Int Moleculas de unión biespecíficas para la terapia anti-angiogénesis

Also Published As

Publication number Publication date
US20140120095A1 (en) 2014-05-01
EA201200548A1 (ru) 2012-12-28
NZ598956A (en) 2014-07-25
UY32920A (es) 2011-04-29
KR20120101375A (ko) 2012-09-13
MA33607B1 (fr) 2012-09-01
AP2012006188A0 (en) 2012-04-30
WO2011039370A1 (en) 2011-04-07
JP2016026207A (ja) 2016-02-12
CN105037542A (zh) 2015-11-11
JP5833009B2 (ja) 2015-12-16
CA2775422A1 (en) 2011-04-07
US20110172398A1 (en) 2011-07-14
AU2010302589A1 (en) 2012-04-19
CN102639566A (zh) 2012-08-15
IN2012DN02752A (es) 2015-09-18
CL2012000826A1 (es) 2012-10-19
BR112012007239A2 (pt) 2019-09-24
EP2483314A1 (en) 2012-08-08
IL218542A0 (en) 2012-05-31
JP2013506411A (ja) 2013-02-28
PH12012500525A1 (en) 2012-11-26
CN102639566B (zh) 2015-07-22
TW201124533A (en) 2011-07-16
MX2012003897A (es) 2012-05-08
NZ626302A (en) 2015-09-25
TN2012000145A1 (en) 2013-09-19
AR078515A1 (es) 2011-11-16
PE20121024A1 (es) 2012-08-10

Similar Documents

Publication Publication Date Title
ECSP12011835A (es) Moléculas de unión biespecíficas para la terapia anti-angiogénesis.
ECSP13013001A (es) Moléculas de unión biespecíficas que se unen a vegf y ang2.
UY33588A (es) Moleculas de union a vegf
AR078516A1 (es) Moleculas de union a dll-4 (ligando 4 de tipo delta)
AR134186A2 (es) Un anticuerpo anti-csf-1r, un proceso para producirlo, una composición farmacéutica que lo comprende, una secuencia de adn aislado, un vector de expresión o clonación y una célula hospedadora
UY33997A (es) Moléculas de unión biespecíficas que se unen a dii4 y ang2
BR112014023415A2 (pt) moléculas que se ligam a ang2
CL2008001674A1 (es) Dominio variable simple (dab) de inmunoglobulina anti-fator de crecimiento endotlial vascular (vegf); acido nucleoico que lo codifica; vector y celula huesped; metodo de produccion; antagonosta de vegf que comprende el dab; composiicon que comprende al antagonista; y uso del antagonista para prepara un medicamento.
BR112015012933A2 (pt) proteínas de ligação ao antígeno bcma
EA201270720A1 (ru) Модуляторы рецептора андрогенов и их применение
AR088512A1 (es) Anticuerpos dirigidos contra el tnf
EP2603235A4 (en) Novel vaccine adjuvants based on targeting adjuvants to antibodies directly to antigen-presenting cells
ECSP14020402A (es) Polipéptidos de unión a cx3cr1
EA201492101A1 (ru) Антитела против fcrn
DOP2011000333A (es) Inmunoglobulina con dominio variable dual y usos de la mismas
BR112014026740A8 (pt) anticorpo, composição, método para fornecer um anticorpo com adcc realçada, e, uso de um anticorpo
EA201690992A1 (ru) Антитела, специфичные к fcrn
AR090668A1 (es) Anticuerpo anti-adamts-5, derivados y usos del mismo
MX2011004245A (es) Composicion para dirigirse a las celulas dendriticas.
BR112014024275A2 (pt) "aptâmeros para pdgf e vegf, construtos de aptâmeros e seus usos"